Skip to main content
. 2013 Jun 17;110(27):11091–11096. doi: 10.1073/pnas.1222251110

Fig. 2.

Fig. 2.

DOX up-regulates CD73 and CD39 expression on tumor cells. (A) MDA-MB-231 cells were treated for 48 h with DOX at increasing doses with or without the cyclic AMP-responsive element binding inhibitor naphtol-AS-E (10 nM). Cell-surface CD73 or (B) CD39 up-regulation (relative to untreated cells) was then measured by flow cytometry. Means ± SEs of triplicate are shown (*P < 0.05 by Mann–Whitney test). (C) MDA-MB-231 cells were treated with DOX at increasing doses for 48 h and CD73 activity, following addition of AMP (250 µM) with or without APCP (100 µM), was measured using a Malachite green phosphate detection kit. Means ± SEs of triplicate are shown (*P < 0.05 by Mann–Whitney test). Results are representative of two individual experiments. (D) CD73 and (E) CD39 up-regulation (maximum fold increase relative to untreated cells ± SEs) in response to DOX, oxaliplatin (OXA), cisplatin (CIS), 5-FU, PAC, and cyclophosphamide (CPX) in human breast cancer cells (*P < 0.05 comparing DOX to each drug). (F) CD73 and CD39 up-regulation in response to DOX, 5-FU, and CPX in human melanoma (LOX-1MV1, A2058) and leukemia (KASUMI-1 and RPMI-8226) cells.